Search research articles
Contact Us
Filters
Showing results (101-110 of 352) with videos related to
Page
of 36
Sort By:
Journal of Crohn'S & Colitis
|
November 9, 2025
Addition of baseline histology and fecal calprotectin does not reduce placebo rates in ulcerative colitis clinical trials: post-hoc analysis of patient-level data
Emily C L Wong, John K Marshall, Christopher Ma, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association
|
June 5, 2026
Comparing Onset of Efficacy of Biologic and Small Molecule Therapies in Biologic-Naïve Ulcerative Colitis: A Post-hoc Analysis
Emily C L Wong, Vipul Jairath, Parambir S Dulai, et al.
The American Journal of Gastroenterology
|
February 10, 2016
Systematic Review and Meta-Analysis: Infliximab or Cyclosporine as Rescue Therapy in Patients With Severe Ulcerative Colitis Refractory to Steroids
Neeraj Narula, John K Marshall, Jean-Frederic Colombel, et al.
The American Journal of Gastroenterology
|
April 29, 2015
Lack of utility of symptoms and signs at first presentation as predictors of inflammatory bowel disease in secondary care
Alexander C Ford, Paul Moayyedi, Premysl Bercik, et al.
Vaccines
|
May 28, 2022
Course of Fecal Calprotectin after mRNA SARS-CoV-2 Vaccination in Patients with Inflammatory Bowel Diseases
Jagoda Pokryszka, Angelika Wagner, Ursula Wiedermann, et al.
United European Gastroenterology Journal
|
June 2, 2021
The impact of ustekinumab on extraintestinal manifestations of Crohn's disease: A post hoc analysis of the UNITI studies
Neeraj Narula, Achuthan Aruljothy, Emily C L Wong, et al.
Inflammatory Bowel Diseases
|
September 30, 2022
Ulcer Size After Induction Therapy Performs Better Than Symptom Assessment for Prediction of One Year Endoscopic Remission in Crohn's Disease: A Post Hoc Analysis
Cara Pray, Emily C L Wong, Achuthan Aruljothy, et al.
Zeitschrift Fur Gastroenterologie
|
August 14, 2018
[Ustekinumab - Current position]
Britta Siegmund, Christoph Högenauer, Gottfried Novacek, et al.
European Journal of Gastroenterology & Hepatology
|
December 4, 2025
Patients with ulcerative colitis that have endoscopic Mayo score 1 and active histologic inflammation have similar outcomes to mild-moderate patients with Mayo score 2: a post hoc analysis of the VARSITY trial
Emily C L Wong, Nazmus Khan, Parambir S Dulai, et al.
The American Journal of Gastroenterology
|
February 2, 2026
Infliximab and Upadacitinib Demonstrate Superior Early Onset of Efficacy in Biologic-Naïve Ulcerative Colitis with Severe Endoscopic Disease
Emily C L Wong, Vipul Jairath, Parambir S Dulai, et al.
Page
of 36
Search research articles
Search
Showing results (101-110 of 352) with videos related to
Sort By:
Page
of 36
Journal of Crohn'S & Colitis
|
November 9, 2025
Addition of baseline histology and fecal calprotectin does not reduce placebo rates in ulcerative colitis clinical trials: post-hoc analysis of patient-level data
Emily C L Wong, John K Marshall, Christopher Ma, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association
|
June 5, 2026
Comparing Onset of Efficacy of Biologic and Small Molecule Therapies in Biologic-Naïve Ulcerative Colitis: A Post-hoc Analysis
Emily C L Wong, Vipul Jairath, Parambir S Dulai, et al.
The American Journal of Gastroenterology
|
February 10, 2016
Systematic Review and Meta-Analysis: Infliximab or Cyclosporine as Rescue Therapy in Patients With Severe Ulcerative Colitis Refractory to Steroids
Neeraj Narula, John K Marshall, Jean-Frederic Colombel, et al.
The American Journal of Gastroenterology
|
April 29, 2015
Lack of utility of symptoms and signs at first presentation as predictors of inflammatory bowel disease in secondary care
Alexander C Ford, Paul Moayyedi, Premysl Bercik, et al.
Vaccines
|
May 28, 2022
Course of Fecal Calprotectin after mRNA SARS-CoV-2 Vaccination in Patients with Inflammatory Bowel Diseases
Jagoda Pokryszka, Angelika Wagner, Ursula Wiedermann, et al.
United European Gastroenterology Journal
|
June 2, 2021
The impact of ustekinumab on extraintestinal manifestations of Crohn's disease: A post hoc analysis of the UNITI studies
Neeraj Narula, Achuthan Aruljothy, Emily C L Wong, et al.
Inflammatory Bowel Diseases
|
September 30, 2022
Ulcer Size After Induction Therapy Performs Better Than Symptom Assessment for Prediction of One Year Endoscopic Remission in Crohn's Disease: A Post Hoc Analysis
Cara Pray, Emily C L Wong, Achuthan Aruljothy, et al.
Zeitschrift Fur Gastroenterologie
|
August 14, 2018
[Ustekinumab - Current position]
Britta Siegmund, Christoph Högenauer, Gottfried Novacek, et al.
European Journal of Gastroenterology & Hepatology
|
December 4, 2025
Patients with ulcerative colitis that have endoscopic Mayo score 1 and active histologic inflammation have similar outcomes to mild-moderate patients with Mayo score 2: a post hoc analysis of the VARSITY trial
Emily C L Wong, Nazmus Khan, Parambir S Dulai, et al.
The American Journal of Gastroenterology
|
February 2, 2026
Infliximab and Upadacitinib Demonstrate Superior Early Onset of Efficacy in Biologic-Naïve Ulcerative Colitis with Severe Endoscopic Disease
Emily C L Wong, Vipul Jairath, Parambir S Dulai, et al.
Page
of 36